InvestorsHub Logo
Followers 2
Posts 188
Boards Moderated 0
Alias Born 01/09/2019

Re: dcaf7 post# 188

Wednesday, 01/25/2023 11:01:44 AM

Wednesday, January 25, 2023 11:01:44 AM

Post# of 575
The IDH1/IDH2 inhibitors are limited. Yes they generate CRs, but most AML patients have multiple mutations, not just IDH1 or IDH2. They are very susceptible to relapse. I believe that TUSP will be much more effective in first line AML if it proves to be safe with HMA + Ven (which I expect). I expect the range of AML patients that will respond to the triplet to include the IDH2 and possible the IDH1mut patients.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent APTO News